ABIVAX is trading 4.4% down at €78.10, amid broader market and biotech-sector weakness rather than a clear new company-specific catalyst. - Global stocks were lower on October 23 amid geopolitical tensions, higher oil prices and weaker French business activity. - Recent coverage mentioned analyst-target changes and lower reported stakes, but does not establish either as the cause of this move. No trading-volume information was available.